Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024
Eupraxia Pharmaceuticals (TSX/NASDAQ: EPRX) announced its participation at the American College of Gastroenterology Annual Scientific Meeting 2024 in Philadelphia, presenting two significant posters. The first poster (P2209), which received a Presidential Award, focuses on EP-104GI's pharmacokinetics and tolerability in mini-pigs. The second poster (P3911), designated as an 'Abstract of Interest,' presents efficacy and pharmacokinetic results from the RESOLVE Phase 1b/2a study's first four cohorts. Both presentations, scheduled for October 28-29, 2024, showcase the company's work on their extended-release fluticasone formulation for treating Eosinophilic Esophagitis.
Eupraxia Pharmaceuticals (TSX/NASDAQ: EPRX) ha annunciato la sua partecipazione all'American College of Gastroenterology Annual Scientific Meeting 2024 a Philadelphia, presentando due poster significativi. Il primo poster (P2209), che ha ricevuto un Premio Presidenziale, si concentra sulla farmacocinetica e sulla tollerabilità di EP-104GI nei mini-maiali. Il secondo poster (P3911), designato come 'Abstract of Interest', presenta i risultati di efficacia e farmacocinetici dei primi quattro gruppi dello studio RESOLVE fase 1b/2a. Entrambe le presentazioni, programmate per il 28-29 ottobre 2024, mettono in evidenza il lavoro dell'azienda sulla loro formulazione di fluticasone a rilascio prolungato per il trattamento dell'Esofagite Eosinofila.
Eupraxia Pharmaceuticals (TSX/NASDAQ: EPRX) anunció su participación en la Reunión Científica Anual del Colegio Americano de Gastroenterología 2024 en Filadelfia, presentando dos carteles significativos. El primer cartel (P2209), que recibió un Premio Presidencial, se centra en la farmacocinética y tolerabilidad de EP-104GI en mini-cerdos. El segundo cartel (P3911), designado como 'Resumen de Interés', presenta los resultados de eficacia y farmacocinética de los primeros cuatro grupos del estudio RESOLVE fase 1b/2a. Ambas presentaciones, programadas para el 28-29 de octubre de 2024, destacan el trabajo de la empresa en su formulación de fluticasona de liberación prolongada para el tratamiento de la Esofagitis Eosinofílica.
유프락시아 제약 (TSX/NASDAQ: EPRX)는 필라델피아에서 열리는 2024년 미국 위장병학회 연례학술대회에 참가하여 두 개의 중요한 포스터를 발표한다고 발표했습니다. 첫 번째 포스터(P2209)는 대통령상을 수상했으며 EP-104GI의 약리학적 동태 및 미니 돼지에서의 내약성을 다루고 있습니다. 두 번째 포스터(P3911)는 '관심 초록'으로 지정되었으며, RESOLVE 1b/2a 연구의 첫 네 집단에서의 유효성과 약리학적 동태 결과를 제공합니다. 2024년 10월 28-29일에 예정된 두 발표는 호산구 식도염 치료를 위한 지속 방출 플루티카손 제제에 대한 회사의 작업을 소개합니다.
Eupraxia Pharmaceuticals (TSX/NASDAQ: EPRX) a annoncé sa participation à la Réunion Scientifique Annuelle du Collège Américain de Gastroentérologie 2024 à Philadelphie, présentant deux affiches significatives. La première affiche (P2209), qui a reçu un Prix Présidentiel, se concentre sur la pharmacocinétique et la tolérance d'EP-104GI chez des mini-cochons. La deuxième affiche (P3911), désignée comme 'Résumé d'Intérêt', présente des résultats d'efficacité et de pharmacocinétique des quatre premières cohortes de l'étude RESOLVE phase 1b/2a. Les deux présentations, prévues pour le 28-29 octobre 2024, mettent en avant le travail de l'entreprise sur leur formulation de fluticasone à libération prolongée pour traiter l'œsophagite éosinophilique.
Eupraxia Pharmaceuticals (TSX/NASDAQ: EPRX) gab bekannt, dass sie am American College of Gastroenterology Annual Scientific Meeting 2024 in Philadelphia teilnehmen wird und zwei bedeutende Posters präsentieren wird. Das erste Poster (P2209), das einen Präsidentenpreis erhielt, beschäftigt sich mit der Pharmakokinetik und Verträglichkeit von EP-104GI bei Minischweinen. Das zweite Poster (P3911), das als 'Abstract of Interest' gekennzeichnet ist, präsentiert die Wirksamkeits- und Pharmakokinetik-Ergebnisse der ersten vier Kohorten der RESOLVE-Phase 1b/2a Studie. Beide Präsentationen, die für den 28.-29. Oktober 2024 geplant sind, zeigen die Arbeiten des Unternehmens an ihrer verzögert freisetzenden Fluticason-Formulierung zur Behandlung der eosinophilen Ösophagitis.
- None.
- None.
The event is a premier gastrointestinal ("GI") clinical meeting and the ACG is a recognized leader in educating GI professionals and the general public about digestive disorders.
Poster Details:
Poster Number: | P2209 |
Poster Title: | Pharmacokinetics and Local Tolerability of EP-104GI, an Extended-Release Formulation of Fluticasone for Treatment of Eosinophilic Esophagitis, after Intra-Esophageal Injection in Mini-Pigs |
Session Date & Time: | Monday, October 28, 2024, 10:30 a.m. – 4:00 p.m. ET |
Presenter: | Dr. Amanda Malone |
This is a non-clinical poster and received a Presidential Award from the conference, which is a distinction for high quality, novel, unique, and interesting research.
Poster Number: | P3911 |
Poster Title: | Efficacy and Pharmacokinetic Results From Ongoing Dose Escalation in RESOLVE, a Phase 1b/2a Study of EP-104GI (Extended-Release Fluticasone Propionate Intra-Esophageal Injection) for Eosinophilic Esophagitis |
Session Date & Time: | Tuesday, October 29, 2024, 10:30 a.m. – 4:00 p.m. ET |
Presenter: | Dr. Evan Dellon |
This poster features data from cohorts one through four from the RESOLVE trial and was declared an "Abstract of Interest" by the conference.
Both posters will be available on Eupraxia's website at:
https://eupraxiapharma.com/our-science/clinical-trials-and-publications/default.aspx.
About Eupraxia Pharmaceuticals Inc.
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the DiffuSphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's DiffuSphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas.
Eupraxia's EP-104GI is currently in a Phase 1b/2a trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis ("EoE"). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: www.eupraxiapharma.com.
Notice Regarding Forward-looking Statements and Information
This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", "suggests", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes", "potential" or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements in this news release include statements regarding the details of the Company's presentations at the ongoing ACG Annual Scientific Meeting 2024; the Company's product candidates, including their expected benefits to patients with respect to safety, tolerability; efficacy and duration; the results gathered from studies and trials of Eupraxia's product candidates; the potential for the Company's technology to impact the drug delivery process; potential market opportunity for the Company's products; and potential pipeline indications. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the Company's technology may not be successful for its intended use; the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company's clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its products and services; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/eupraxia-pharmaceuticals-to-present-at-american-college-of-gastroenterology-annual-scientific-meeting-2024-302288126.html
SOURCE Eupraxia Pharmaceuticals Inc.
FAQ
What are the two posters Eupraxia Pharmaceuticals (EPRX) is presenting at ACG 2024?
When is Eupraxia Pharmaceuticals (EPRX) presenting at the ACG 2024 meeting?
What recognition did Eupraxia's (EPRX) posters receive at ACG 2024?
What is EP-104GI being developed for by Eupraxia (EPRX)?
